Location
https://www.kennesaw.edu/ccse/events/computing-showcase/sp24-cday-program.php
Document Type
Event
Start Date
25-4-2024 4:00 PM
Description
Multiple Myeloma is a rare form of bone marrow cancer where plasma cells accumulate in the blood stream attacking the skeletal system, nervous system, and kidneys of predominantly African Americans. The disease results in high mortality rates within 5 years of initial diagnosis. Multiple Myeloma has subtle symptoms of bone pain; doctors often send people to physical therapy missing the diagnosis. Current research on the International Myeloma Foundation website includes summaries of blood tests of Multiple Myeloma patients. This study seeks to identify the best blood test predictors of Stage 3, the most aggressive stage of Multiple Myeloma. The cost savings are also considered of using these blood tests as an initial screening as compared to a bone marrow biopsy. Using 21 blood test results and demographic information on 203 Multiple Myeloma patients from 2008-2019 in Algeria, Logistic Regression was conducted to identify the best predictor of Stage 3 Multiple Myeloma versus Stage 1 and 2. Wald Confidence Intervals were used to estimate the odds ratios. Cost savings were calculated by determining the cost differential of less invasive blood tests versus the more invasive bone marrow biopsy. The Logistic Model was able to distinguish 65.43% of the time between whether patients have Stage 3 versus Stages 1 and 2. The odds of having Stage 3 Multiple Myeloma increase 1.04 to 1.56 times for each one g/dL decrease in MCHC. Lower patient MCHC levels are more indicative of the patient having Stage 3. Using an MCHC blood test has an estimated cost savings of $1734 per patient as compared to a bone marrow biopsy. Testing a patient with bone pain for MCHC can facilitate earlier Multiple Myeloma diagnosis, allowing physicians to administer earlier treatments, thereby improving patients’ longevity and quality of life while coping with the disease.
Included in
UR-12 Multiple Myeloma: Increase Longevity and Quality of Life through Early Detection
https://www.kennesaw.edu/ccse/events/computing-showcase/sp24-cday-program.php
Multiple Myeloma is a rare form of bone marrow cancer where plasma cells accumulate in the blood stream attacking the skeletal system, nervous system, and kidneys of predominantly African Americans. The disease results in high mortality rates within 5 years of initial diagnosis. Multiple Myeloma has subtle symptoms of bone pain; doctors often send people to physical therapy missing the diagnosis. Current research on the International Myeloma Foundation website includes summaries of blood tests of Multiple Myeloma patients. This study seeks to identify the best blood test predictors of Stage 3, the most aggressive stage of Multiple Myeloma. The cost savings are also considered of using these blood tests as an initial screening as compared to a bone marrow biopsy. Using 21 blood test results and demographic information on 203 Multiple Myeloma patients from 2008-2019 in Algeria, Logistic Regression was conducted to identify the best predictor of Stage 3 Multiple Myeloma versus Stage 1 and 2. Wald Confidence Intervals were used to estimate the odds ratios. Cost savings were calculated by determining the cost differential of less invasive blood tests versus the more invasive bone marrow biopsy. The Logistic Model was able to distinguish 65.43% of the time between whether patients have Stage 3 versus Stages 1 and 2. The odds of having Stage 3 Multiple Myeloma increase 1.04 to 1.56 times for each one g/dL decrease in MCHC. Lower patient MCHC levels are more indicative of the patient having Stage 3. Using an MCHC blood test has an estimated cost savings of $1734 per patient as compared to a bone marrow biopsy. Testing a patient with bone pain for MCHC can facilitate earlier Multiple Myeloma diagnosis, allowing physicians to administer earlier treatments, thereby improving patients’ longevity and quality of life while coping with the disease.